Skip to content

Usefulness of Galls in abnormal vaginal discharge

Comparative evaluation of Kakrasingi and Metronidazole in Sayalan al-rahim - -

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/01/023065
Enrollment
60
Registered
2020-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N768- Other specified inflammation of vagina and vulva

Interventions

Intervention1: Kakrasingi _ (Pistacia integerrima Stewart ex Brandis): Fine powder of kakrasingi (1g) in capsules and will be adminstered orally twice daily for 7 days Control Intervention1: Tab M

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Married women in reproductive aged (18-45 years) Patients who fulfil at least three out of the four Amsel criteria (homogenous vaginal discharge, vaginal PH > 4.5, positive whiff or amine test and presence of clue cells) to diagnose bacterial vaginosis. Patients with positive Gram stain for BV by Nugent score

Exclusion criteria

Exclusion criteria: Abnormal uterine bleeding, menstruation, frequent vaginal douche, alcohol and coumarin anticoagulants. Pregnancy and lactation, multiple sexual partners , on oral contraceptive pills and intrauterine devices. Specifc diseases such as liver disease, kidney and central nervous system diseases, blood dyscrasia, diabetes,immune defciency, and known venereal disease. History of hypersensitivity to metronidazole tablets. • Unwilling to abstain from alcohol for 3 days after treatment. Received concomitant antimicrobial therapy (topical or oral), or received a recent course (within previous 14 days) of antimicrobial or antifungal therapy.

Design outcomes

Primary

MeasureTime frame
Amsel criteria () Normal vaginal discharge, 2) negative 10% potassium hydroxide whiff test, and 3) clue cells less than 20% of total epithelial cells on microscopic examination of the vaginal wet mount using saline) after treatment.)Timepoint: 8th day (post test)

Secondary

MeasureTime frame
Microbiologic cure, defined as a Nugent score of 0â??3 Therapeutic cure, defined as meeting criteria for both clinical and microbiologic cure after treatment. Vaginal symptom scale (VSS). Timepoint: 8th day (post test)

Countries

India

Contacts

Public ContactArshiya Sultana

National Institute of Unani Medicine

drarshiya@yahoo.com9740915911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026